MedTrace Logo

Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

NCT02988297 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).

Conditions

Interventions

DRUG

RNS60

Nebulized RNS60 will be administered by daily inhalation for 24 weeks.

DRUG

Placebo

Nebulized Placebo will be administered by daily inhalation for 24 weeks.

Sponsors & Collaborators

  • Revalesio Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2028-11-30
Completion
2028-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02988297 on ClinicalTrials.gov